Novartis blood cancer drug given EU nod
March 17, 2015Sales and Marketing Cancer, EU, Jakavi, Novartis, oncology, polycythemia vera, ruxolitinib
Novartis’ blood cancer drug Jakavi has been given the green light in Europe to treat adult patients with polycythemia vera …
Sanofi affiliate to supply 37 million vaccines
March 17, 2015Manufacturing and Production, Sales and Marketing GAVI, Sanofi, Sanofi Pasteur, Shantha Biotechnics, shan5, vaccines
Sanofi’s vaccines division Sanofi Pasteur has confirmed its affiliate Shantha Biotechnics in India has delivered the first 400,000 doses of …
Big pharma partners with government over $100m dementia fund
March 17, 2015Research and Development, Sales and Marketing Alzheimer's, Biogen IDEC, GSK, J&J, JJ, Pfizer, government, jp morgan, lilly
Lilly, Pfizer, GSK, J&J and Biogen Idec are set to join a $100m Dementia Discovery Fund to boost research into …
23andMe assigns chief scientific officer to new unit
March 17, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing 23andm3, Richard Scheller
US personal genetics firm 23andMe has created a new therapeutics group and appointed pharma veteran Richard Scheller as chief science …
23andMe to move into drug development
March 16, 2015Medical Communications, Research and Development, Sales and Marketing 23andME, DNA, Genentech, Pfizer, google
The Google-backed DNA test company 23andMe has announced plans to start using genetic data to design new drugs. In recent …
NHS is struggling to improve cancer care
March 16, 2015Sales and Marketing CRUK, Cancer, Department of Health, NHS, NHS England, oncology
The Department of Health and NHS England are struggling with the demand required to improve its cancer services according to …
Sanofi and Amgen cholesterol drugs shine
March 16, 2015Sales and Marketing Amgen, PCSK9, Repatha, Sanofi, alirocumab, evolocumab, praluent
Two large Phase III studies of Sanofi’s Praluent and Amgen’s Repatha have found the biologic cholesterol-lowering drugs are more effective …
Boehringer eyes Ofev success in IPF and beyond
March 16, 2015Sales and Marketing Boehringer, Esbriet, Roche, ingelheim, inpulsis, ipd, ofev
Experts say the launch of Boehringer Ingelheim’s new treatment for idiopathic pulmonary fibrosis (IPF) offers stiff competition to Roche’s Esbriet …
Drug development contracts: can lessons be learned from healthcare delivery?
March 16, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CCG, CRO, Les Rose, NHS, drug development, trials
There is a very good question to ask at the beginning of every project: “What does success look like?” If …
Recipharm appoints quality management VP
March 16, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Recipharm, thomas beck
Contract development and manufacturing organisation Recipharm has appointed Thomas Beck to the new senior role of vice president of quality …
Pharma pays £310 million underwriting UK meds bill
March 13, 2015Sales and Marketing ABPI, NHS, PPRS, body, department, health pricing, pharma
Pharma has made a fourth quarter payment of £81 million to underwrite the 2014 UK medicines bill under the Pharmaceutical …
BMS resubmits hepatitis C drug
March 13, 2015Sales and Marketing BMS, NDA, daclatasvir gilead, hepatitis C, sovaldi
Bristol-Myers Squibb has resubmitted its hepatitis C (HCV) treatment for FDA approval despite previously backing out, as it spots a …
Blow for Pfizer as Lyrica misses target
March 13, 2015Sales and Marketing FDA, Lyrica, Pfizer, fibromyalgia, pain, pregablin
A late-stage study of Pfizer’s Lyrica has failed to demonstrate it has any significant pain reduction in patients with fibromyalgia. …
GSK sells off stake in Aspen for $853m
March 13, 2015Sales and Marketing Africa, China, GSK, Novartis, Singapore, aspen, merger, redfern
GlaxoSmithKline has sold off half its stake in South Africa’s Aspen Pharmacare in a move that will net the British …
Takeda gets NICE nod for bowel treatment
March 13, 2015Sales and Marketing NHS, NICE, Takeda, enyyvio, vedolizumab
Takeda’s Entyvio becomes the first NICE approved gut-selective treatment for UK patients with ulcerative colitis (UC) – a long-term condition …
AXON Communications adds five to London team
March 13, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Axon, bilotta, burns, peregrin, treadwell, ura
UK healthcare comms and PR firm AXON Communications has added five new members to its team in London. Lucie Burns …
J&J pleads guilty over children’s contaminated medicine
March 12, 2015Manufacturing and Production, Sales and Marketing FDA, J&J, JJ, McNeil, OTC, Tylenol, consta, hamburg, recall
Johnson & Johnson’s consumer division McNeil has pleaded guilty and will pay fines of $25 million for wrongdoings regarding its …
NHS backtracks on Cancer Drugs Fund de-listings
March 12, 2015Sales and Marketing Afinitor, CDF, Cancer Drugs Fund, England, Halaven, NHS, Novartis, everolimus
NHS England is expected to perform a U-turn on several decisions to remove treatments from the cancer drugs fund when …
Endo attempts to outbid Valeant for Salix Pharma
March 12, 2015Sales and Marketing Endo, Valeant, merger, outbid, pharma, salix
Endo has joined the race for Salix, the firm that Valeant reached a $14.5 billion agreement to purchase last month. …
GSK picks Singapore for Asian hub
March 12, 2015Manufacturing and Production, Research and Development, Sales and Marketing Asia, GSK, Singapore, Takeda, Witty, emerging markets
Despite GlaxoSmithKline’s ongoing troubles in Asia it has decided to establish a new HQ in Singapore to bolster its presence …
Latest content
Migraine annual economic and quality-of-life burden in UK
bit.bio expands human heart cell portfolio through myriamed partnership
Phoenix Labs acquires Kent Pharma
Astoriom acquires Sampled’s UK stability storage operations
